Zobrazeno 1 - 10
of 124 604
pro vyhledávání: ''
Autor:
Lorinda Simms, Shehkar Patil, David R. Gandara, Anders Mellemgaard, Raghunadharao Digumarti, Bonne Biesma, Johan Vansteenkiste, Mauro Zukin, Joachim von Pawel, Katherine P. Sugarman, Keunchil Park, Christian Manegold, Filippo de Marinis, Tuncay Göksel, Janusz Rolski, Piotr Serwatowski, Jin S. Lee, Giorgio V. Scagliotti, Ulrich Gatzemeier, Purvish M. Parikh
Publikováno v:
Journal of Clinical Oncology. 41:2458-2466
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non–small-cell lung cancer (NSCLC). Phase II studies of pemetrexed plus platinum compounds have also shown activity in this setting. PATIENTS AND METHODS
Autor:
Ulrich Gatzemeier, Michael Boyer, Paolo Paoletti, Salih Emri, Christian Manegold, Claude Denham, Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski, Clet Niyikiza, E. Kaukel, Pierre Ruffié
Publikováno v:
Journal of Clinical Oncology. 41:2125-2133
PURPOSE Patients with malignant pleural mesothelioma, a rapidly progressing malignancy with a median survival time of 6 to 9 months, have previously responded poorly to chemotherapy. We conducted a phase III trial to determine whether treatment with
Autor:
Garth W. Strohbehn, Robert Holleman, Jennifer Burns, Mandi L. Klamerus, Michael J. Kelley, Eve A. Kerr, Nithya Ramnath, Timothy P. Hofer
Publikováno v:
JAMA oncology. 8(11)
ImportanceExtended-interval dosing of pembrolizumab (400 mg every 6 weeks) was approved by US Food and Drug Administration (FDA) in April 2020 as an alternative to standard-interval dosing (200 mg every 3 weeks). Extended-interval dosing may enhance
Autor:
Andrea De Giglio, Valeria Grandinetti, Marta Aprile, Greta Borelli, Anita Campus, Anna Laura Croci Chiocchini, Marco Busutti, Gisella Vischini, Alessandro Di Federico, Francesca Sperandi, Barbara Melotti, Andrea Ardizzoni, Gaetano La Manna, Francesco Gelsomino
Publikováno v:
Lung Cancer. 174:91-96
The combination of immune-checkpoint inhibitors (ICI) and platinum-pemetrexed chemotherapy (CT) in first-line setting improved survival outcomes of advanced non-small cell lung cancer (NSCLC) patients. Among the various adverse events, renal toxicity
Autor:
Hánah N Rier, Marieke C Meinardi, Joost van Rosmalen, Peter E Westerweel, Eva de Jongh, Jos J E M Kitzen, Joan van den Bosch, Marija Trajkovic, Mark-David Levin
Publikováno v:
The oncologist, 27(11), e878-e888. AlphaMed Press
Background Maintaining functional status is among the most important patient-centered outcomes for older adults with cancer. This study investigated the association between comprehensive geriatric assessment (CGA) and progressive disease or decline o
Autor:
Charles Faselis, Joel A. Nations, Charity J. Morgan, Jared Antevil, Jeffrey M. Roseman, Sijian Zhang, Gregg C. Fonarow, Helen M. Sheriff, Gregory D. Trachiotis, Richard M. Allman, Prakash Deedwania, Qing Zeng-Trietler, Daniel D. Taub, Amiya A. Ahmed, George Howard, Ali Ahmed
Publikováno v:
JAMA Oncol
ImportanceThe US Preventive Services Task Force does not recommend annual lung cancer screening with low-dose computed tomography (LDCT) for adults aged 50 to 80 years who are former smokers with 20 or more pack-years of smoking who quit 15 or more y
Autor:
Kensuke, Yamamura, Toru, Beppu, Keijiro, Inoue, Kazuki, Matsumura, Eri, Oda, Yasunori, Nagayama, Toshihiko, Motohara, Hideaki, Miyamoto, Yoshihiro, Komohara, Hirohisa, Okabe, Tatsunori, Miyata, Takatoshi, Isiko
Publikováno v:
Anticancer Research. 42:5663-5670
Hepatocellular carcinoma (HCC) with bile duct tumor thrombus (BDTT) is highly malignant; therefore, continual, multidisciplinary treatments are essential.In this study, two 78- and 81-year-old men were treated with the Vater papilla-preserving strate
Publikováno v:
Cancer Research and Treatment. 54:1030-1037
PurposeAlthough lung cancer incidences in female never-smokers have increased, few studies focus on explicit investigation. We aimed to investigate the relationship between long-term exposure to ambient particulate matter sized 10 μm or less in diam
Autor:
Neeraj Agarwal, Catherine M. Tangen, Maha H.A. Hussain, Shilpa Gupta, Melissa Plets, Primo N. Lara, Andrea L. Harzstark, Przemyslaw W. Twardowski, Channing J. Paller, Dylan Zylla, Matthew R. Zibelman, Ellis Levine, Bruce J. Roth, Amir Goldkorn, Daniel A. Vaena, Manish Kohli, Tony Crispino, Nicholas J. Vogelzang, Ian M. Thompson, David I. Quinn
Publikováno v:
Journal of Clinical Oncology. 40:3301-3309
PURPOSE Orteronel (TAK-700) is a nonsteroidal 17,20-lyase inhibitor suppressing androgen synthesis. We evaluated the clinical benefit of orteronel when added to androgen deprivation therapy (ADT) in patients with newly diagnosed metastatic hormone-se
Autor:
William A. Hall, Theodore G. Karrison, Seth A. Rosenthal, Mahul B. Amin, Leonard G. Gomella, James A. Purdy, A. Oliver Sartor, Jeff M. Michalski, Mark G. Garzotto, Carmen Bergom, Ashesh B. Jani, Colleen A.F. Lawton, Jeffry P. Simko, Joan K. Moore, Elizabeth M. Gore, W. Robert Lee, Paul L. Nguyen, Brita L. Danielson, Howard M. Sandler, Felix Y. Feng
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:266-274
The immunoinflammatory state has been shown to be associated with poor outcomes after radiation therapy (RT). We conducted an a priori designed validation study using serum specimens from Radiation Therapy Oncology Group (RTOG) 0521. It was hypothesi